NEW YORK (GenomeWeb) – German start-up SpinDiag said on Thursday that it has raised €1.6 million ($1.9 million) in seed funding.
The financing came from three unnamed private investors and will be used to bring its point-of-care screening system to hospitals from its current laboratory environment, the firm said. The technology called SpinDiag one, is being developed for hospital screening of all clinically relevant antibiotic-resistant bacteria at the time patients are admitted.
According to SpinDiag's website, the platform will be able to detect such bacteria in 30 minutes directly from patient samples and will enable the parallel identification of some of the most prevalent drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and carbapenemase producers.
The system uses centrifugal microfluidic technology to provide laboratory-grade PCR results and has an automated workflow, the company siad.
"The platform characteristic of our product enables a very powerful product pipeline for the point-of-care testing of infectious diseases, such as respiratory tract infections, sepsis, and tuberculosis," Oliver Strohmeier, SpinDiag's cofounder and chief technology officer, said in a statement.
Based in Freiburg, SpinDiag was spun out of the research institute Hahn-Schickard in 2016.